Poliomyelitis: polio eradication: draft decision

EXECUTIVE BOARD EB146/21 Add.1 146th session 24 January 2020 Provisional agenda item 16.1 Poliomyelitis Polio eradication Draft decision The Executive Board is invited to consider the following draft decision: The Executive Board, having considered the report on poliomyelitis: polio eradication;1 noting with great concern the evolving public health emergency associated with the increase in new emergences due to circulating vaccine-derived poliovirus type 2, particularly in parts of Africa; and noting the development of the draft Strategy for Control of cVDPV2 2019–2021, an addendum to the Polio Endgame Strategy 2019–2023,2 to more effectively address the evolving circulating vaccine-derived poliovirus type 2 epidemiology, decided: (1) to request the Director-General to: (a) continue to ensure adequate and uninterrupted supply of oral polio vaccine type 2 to respond to such outbreaks, in line with existing mandates; (b) accelerate the assessment and roll-out of a novel oral polio vaccine type 2 including through the WHO Emergency Use Listing procedure; (c) initiate a transparent and evidence-based process for prioritizing the equitable allocation of limited supplies of novel oral polio vaccine type 2; and, (2) to urge Member States to: (a) expedite the processes for authorizing the importation and use of vaccines to respond to polio outbreaks, including novel oral polio vaccine type 2 on the basis of its emergency use listing; and (b) mobilize domestic financial resources to complement international financial and political commitments. = = = 1 Document EB146/21. 2 Available at http://polioeradication.org/wp-content/uploads/2016/07/GPEI-cVDPV2-DRAFT-Outbreak-Strategy- 20191218-1.pdf (accessed 22 January 2020).